Shares of Nektar Therapeutics (NASDAQ:NKTR) gained on Friday after Jefferies upgraded the stock noting an attractive ...

Virtual Meeting to be held on April 22-23 hosted by B. Riley.Stay Ahead of the Market: Discover outperforming stocks and invest smarter with ...

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) has been assigned a consensus recommendation of “Buy” from the seven analysts that are currently covering the stock, Ratings reports. One equities ...

The company has lost over 63% of its market value in the past six months, but Jefferies analyst Roger Song cited encouraging ...

Jefferies upgraded Nektar (NKTR) to Buy from Hold with a price target of $2, up from $1. The company’s rezpegaldesleukin will report topline ...

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders.

Nektar Therapeutics (NKTR) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to loss of $0.22 per share a year ago.

Zacks Research boosted their Q1 2025 earnings per share estimates for Nektar Therapeutics in a research note issued on ...

In this article, we are going to take a look at where Nektar Therapeutics (NASDAQ:NKTR) stands against other stocks that Wall Street is calling bullish amid market turmoil. The S&P 500 is down 8.6 ...